These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29206910)

  • 1. State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals.
    Kapadia SN; Jeng PJ; Schackman BR; Bao Y
    Clin Infect Dis; 2018 May; 66(10):1618-1620. PubMed ID: 29206910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.
    Herink MC; Geddes J; Vo K; Zaman A; Hartung DM
    J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560
    [No Abstract]   [Full Text] [Related]  

  • 3. Enforcement of Legal Remedies to Secure Hepatitis C Virus Treatment With Direct-Acting Antiviral Therapies in Correctional Facilities and Medicaid Programs.
    Greenwald R; Waters P; Cayer S
    Public Health Rep; 2020; 135(1_suppl):44S-49S. PubMed ID: 32735189
    [No Abstract]   [Full Text] [Related]  

  • 4. [Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent].
    Weiland O
    Lakartidningen; 2014 Nov; 111(51-52):2280-1. PubMed ID: 25423337
    [No Abstract]   [Full Text] [Related]  

  • 5. Characteristics of Persons Treated for Hepatitis C Using National Pharmacy Claims Data, United States, 2014-2020.
    Teshale EH; Roberts H; Gupta N; Jiles R
    Clin Infect Dis; 2022 Sep; 75(6):1078-1080. PubMed ID: 35171997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A National Hepatitis C Elimination Program in the United States: A Historic Opportunity.
    Fleurence RL; Collins FS
    JAMA; 2023 Apr; 329(15):1251-1252. PubMed ID: 36892976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.
    Auty SG; Shafer PR; Dusetzina SB; Griffith KN
    JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.
    Auty SG; Shafer PR; Griffith KN
    JAMA Health Forum; 2021 Aug; 2(8):e212291. PubMed ID: 35977192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
    Canary LA; Klevens RM; Holmberg SD
    Ann Intern Med; 2015 Aug; 163(3):226-8. PubMed ID: 26121095
    [No Abstract]   [Full Text] [Related]  

  • 11. Early Patterns of Sofosbuvir Utilization by State Medicaid Programs.
    Liao JM; Fischer MA
    N Engl J Med; 2015 Sep; 373(13):1279-81. PubMed ID: 26398092
    [No Abstract]   [Full Text] [Related]  

  • 12. A Novel Strategy for Increasing Access to Treatment for Hepatitis C Virus Infection for Medicaid Beneficiaries.
    Sood N; Ung D; Shankar A; Strom BL
    Ann Intern Med; 2018 Jul; 169(2):118-119. PubMed ID: 29799973
    [No Abstract]   [Full Text] [Related]  

  • 13. State Medicaid Restrictions for Direct-Acting Antiviral Therapy Do Not Impact Posttransplant Outcomes of Recipients of Hepatitis C Virus-Viremic Livers.
    Narasimman M; Goldberg DS
    Liver Transpl; 2021 Jan; 27(1):140-143. PubMed ID: 32979030
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of direct-acting antiviral use for chronic hepatitis C on health care costs in Medicaid: economic model update.
    Roebuck MC
    Am J Manag Care; 2022 Dec; 28(12):630-631. PubMed ID: 36525655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfected and HCV monoinfected patients.
    Rice DP; Ordoveza MA; Palmer AM; Wu GY; Chirch LM
    AIDS Care; 2018 Dec; 30(12):1507-1511. PubMed ID: 30021452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialist and Primary Care Treatment of Hepatitis C Infections in US Medicaid in 2018.
    Kapadia SN; Zhang H; Gonzalez CJ; Sen B; Franco RA; Shapiro MF; Bao Y
    J Gen Intern Med; 2023 Apr; 38(5):1323-1325. PubMed ID: 36323823
    [No Abstract]   [Full Text] [Related]  

  • 17. Restricted Access: State Medicaid Coverage of Sofosbuvir Hepatitis C Treatment.
    Tumber MB
    J Leg Med; 2017; 37(1-2):21-64. PubMed ID: 28910222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What does the pharmacological future of treating chronic hepatitis C look like?
    Heil EL; Hynicka LM; Kottilil S; Tang L
    Expert Rev Clin Pharmacol; 2015; 8(5):605-22. PubMed ID: 26289223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Hepatitis C Infection in Children.
    Pham YH; Rosenthal P
    Adv Pediatr; 2016 Aug; 63(1):173-94. PubMed ID: 27426900
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct-acting antiviral agents for the treatment of HCV.
    Thompson AJ; Locarnini S
    Antivir Ther; 2012; 17(6 Pt B):1105-7. PubMed ID: 23188736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.